Abstract
BACKGROUND:
Keloid is a kind of benign skin fibroproliferative disease with a high recurrence risk. At present, comprehensive therapy is commonly used in treatment, but the high recurrence rate is still an urgent problem to solve. Moreover, the existing comprehensive treatment methods also have various problems, such as high cost, complex process, multiple side effects and so on.